AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02395913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR (200mg, T4)
Description: one tablet once one days fasting administration.
Study NCT02023710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study NCT01287481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain and Body
Description: Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
Study NCT03224481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic reminder
Description: The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
Study NCT03915236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MON4STRAT Strategy
Description: Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
Study NCT03915236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
Study NCT01543139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate+Cytidine-+Creatine-
Description: Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
Study NCT01543139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate+Cytidine-
Description: Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
Study NCT01543139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: Valproate: Week0-8: 300mg/day
Study NCT01315847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant
Description: Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
Study NCT01315847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-4232
Description: Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
Study NCT00234208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy
Study NCT00234208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple chest tube drainage
Study NCT03971500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AntiPlatelet therapy
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
Study NCT03971500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiPlatelet therapy
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
Study NCT02023710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study NCT02023710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
Study NCT02023710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
Study NCT02023710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
Study NCT02704507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: topical application nightly to half the face for 4 weeks
Study NCT02704507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin
Description: topical application nightly for 8 weeks
Study NCT02704507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: topical application nightly for 8 weeks
Study NCT02704507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emollient
Description: topical application nightly to half the face for 4 weeks
Study NCT00767559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: 5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
Study NCT00767559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux:
Description: 2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
Study NCT00767559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery.
Study NCT02541461 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic gastrectomy
Description: (1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
Study NCT03251222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal aplication of dexmedetomidine
Study NCT03251222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Intranasal aplication of 0.9% NaCl
Study NCT01837472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
Study NCT01837472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
Study NCT03052335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam® COLON 2 Capsule
Description: The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
Study NCT03052335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Optical colonoscopy is the standard method for evaluating the colon
Study NCT01739270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular brachial plexus block
Study NCT02272816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC-10
Description: Carboplatin AUC-10 according to the Calvert formula \[10 x (glomerular filtration rate (ml/min) + 25)\]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
Study NCT03208491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serious games use
Description: This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
Study NCT03208491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care of patient
Study NCT04095715 — intervention group
Intervention type: OTHER
Intervention: Haemostasis consultation
Description: Haemostasis consultation
Study NCT04095715 — intervention group
Intervention type: BIOLOGICAL
Intervention: Standard management of patients suspected of thrombopathy
Description: Standard management of patients suspected of thrombopathy
Study NCT00419341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Normal Immunoglobulin for Subcutaneous Administration
Study NCT00331136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-Artesunate
Description: Once a day for 3 days
Study NCT01876550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Calcium Cream, 2%
Description: Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
Study NCT01876550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactroban® Cream
Description: Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
Study NCT01876550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle of test product
Description: Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
Study NCT02991170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unipolar or bipolar radiofrequency ablation+CABG
Description: Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
Study NCT02991170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
Study NCT01651143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAR100842
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT01651143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR100842
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT01651143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SAR100842)
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT02302521 — intervention group
Intervention type: DEVICE
Intervention: Multiplex Sensitivity Encoding (MUSE)
Description: It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100mg/m² po on day6-10
Study NCT03553537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg/m² po on day6-10
Study NCT03971500 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation
Study NCT03971500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: PCI with DES implantation
Study NCT03574961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Support group
Description: Online (remote), web-based support group via private video link.
Study NCT03574961 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: e-Journaling placebo
Description: Online journaling activity.
Study NCT03486353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).
Study NCT03486353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
Study NCT04500119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator
Description: Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
Study NCT03982277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 300 Mg Oral Capsule
Description: High dose rifampicin at 35mg/kg
Study NCT04589897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manuka honey sinus rinse
Description: Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
Study NCT04589897 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sinus rinse
Description: will follow the standard NHS nasal rinse protocol
Study NCT03974074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin infusion
Description: Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
Study NCT03366363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
Study NCT03366363 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
Study NCT04389073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine 40mg
Description: Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04389073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine 40mg
Description: Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04389073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab 240mg
Description: Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04389073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg
Description: Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04389073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50 mg
Description: 50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04389073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 500Mg Oral Tablet
Description: 500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT04389073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study NCT00107276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00107276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT02504372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02504372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT03177538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa and menotropin
Description: Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle
Study NCT03177538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa and lutropin alfa
Description: Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle.
Study NCT05282667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)
Description: A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure
Study NCT03971929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0532
Description: once daily(QD) for 4weeks
Study NCT03971929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR placebo
Description: once daily(QD) for 4weeks
Study NCT03971929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Description: once daily(QD) for 4weeks
Study NCT00905190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 24 mg one time
Study NCT01808469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody
Study NCT01808469 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Monoclonal antibody
Study NCT01946334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anorectal manometry and high-resolution three-dimensional
Study NCT02552576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Voncento
Description: Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate